Ecgonine

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

33 Data

Linezolid	The risk or severity of adverse effects can be increased when Ecgonine is combined with Linezolid.
Furazolidone	The risk or severity of adverse effects can be increased when Ecgonine is combined with Furazolidone.
Procaine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Procaine.
Tranylcypromine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Tranylcypromine.
Phenelzine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Phenelzine.
Minaprine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Minaprine.
Selegiline	The risk or severity of adverse effects can be increased when Ecgonine is combined with Selegiline.
Procarbazine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Procarbazine.
Moclobemide	The risk or severity of adverse effects can be increased when Ecgonine is combined with Moclobemide.
Isocarboxazid	The risk or severity of adverse effects can be increased when Ecgonine is combined with Isocarboxazid.
Rasagiline	The risk or severity of adverse effects can be increased when Ecgonine is combined with Rasagiline.
Pargyline	The risk or severity of adverse effects can be increased when Ecgonine is combined with Pargyline.
Clorgiline	The risk or severity of adverse effects can be increased when Ecgonine is combined with Clorgiline.
Iproniazid	The risk or severity of adverse effects can be increased when Ecgonine is combined with Iproniazid.
Nialamide	The risk or severity of adverse effects can be increased when Ecgonine is combined with Nialamide.
Safinamide	The risk or severity of adverse effects can be increased when Ecgonine is combined with Safinamide.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	The risk or severity of adverse effects can be increased when Ecgonine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Methylene blue	The risk or severity of adverse effects can be increased when Ecgonine is combined with Methylene blue.
Hydracarbazine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Hydracarbazine.
Pirlindole	The risk or severity of adverse effects can be increased when Ecgonine is combined with Pirlindole.
Toloxatone	The risk or severity of adverse effects can be increased when Ecgonine is combined with Toloxatone.
Benmoxin	The risk or severity of adverse effects can be increased when Ecgonine is combined with Benmoxin.
Mebanazine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Mebanazine.
Octamoxin	The risk or severity of adverse effects can be increased when Ecgonine is combined with Octamoxin.
Pheniprazine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Pheniprazine.
Phenoxypropazine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Phenoxypropazine.
Pivhydrazine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Pivhydrazine.
Safrazine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Safrazine.
Caroxazone	The risk or severity of adverse effects can be increased when Ecgonine is combined with Caroxazone.
Harmaline	The risk or severity of adverse effects can be increased when Ecgonine is combined with Harmaline.
Brofaromine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Brofaromine.
Metoclopramide	The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Ecgonine.
Spironolactone	The risk or severity of orthostatic hypotension can be increased when Ecgonine is combined with Spironolactone.

Referensi & Sumber

Synthesis reference: Lowell M. Somers, James E. Wynn, "Derivatives of benzoylecgonine, ecgonine and ecgonidine and methods for preparing and using same." U.S. Patent US5559123, issued December, 1985.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi